UBS upgraded Oscar Health (OSCR) to Neutral from Sell with a price target of $17, up from $12. The firm believes that despite the expiration of the enhanced subsidies, Oscar’s enrollment in the exchanges are holding up better than feared. UBS says the shares are fairly priced at this level.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR:
- Oscar Health: Improved Fundamentals and Earnings Outlook Largely Reflected in Fair Valuation, Supporting Neutral/Hold Rating
- Video: Oil majors rise as U.S. tipped to be ‘strongly involved’ in Venezuela
- Oscar Health upgraded to Equal Weight from Underweight at Barclays
- Oscar Health Extends CEO Bertolini Contract and Compensation
- Oscar faces elevated SEP-driven MLR risk in Georgia, says Jefferies